Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP658274.RAHeeYxZie7t2vMTs576rhCgue65nwwZCARQj5KpHpvZo130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP658274.RAHeeYxZie7t2vMTs576rhCgue65nwwZCARQj5KpHpvZo130_assertion type Assertion NP658274.RAHeeYxZie7t2vMTs576rhCgue65nwwZCARQj5KpHpvZo130_head.
- NP658274.RAHeeYxZie7t2vMTs576rhCgue65nwwZCARQj5KpHpvZo130_assertion description "[In a phase I clinical trial designed to evaluate the feasibility and tolerance of recombinant adenovirus (rAd)mediated gene transfer, we previously demonstrated that a single intratumoral injection of 10(9) PFU of rAd encoding the beta-galactosidase protein (Ad-beta-Gal) induced strong short-term (1-3 months) humoral, helper (Th1 type) and cytotoxic T cell responses specific for the transgene product in patients with advanced lung cancer.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP658274.RAHeeYxZie7t2vMTs576rhCgue65nwwZCARQj5KpHpvZo130_provenance.
- NP658274.RAHeeYxZie7t2vMTs576rhCgue65nwwZCARQj5KpHpvZo130_assertion evidence source_evidence_literature NP658274.RAHeeYxZie7t2vMTs576rhCgue65nwwZCARQj5KpHpvZo130_provenance.
- NP658274.RAHeeYxZie7t2vMTs576rhCgue65nwwZCARQj5KpHpvZo130_assertion SIO_000772 10986563 NP658274.RAHeeYxZie7t2vMTs576rhCgue65nwwZCARQj5KpHpvZo130_provenance.
- NP658274.RAHeeYxZie7t2vMTs576rhCgue65nwwZCARQj5KpHpvZo130_assertion wasDerivedFrom befree-20140225 NP658274.RAHeeYxZie7t2vMTs576rhCgue65nwwZCARQj5KpHpvZo130_provenance.
- NP658274.RAHeeYxZie7t2vMTs576rhCgue65nwwZCARQj5KpHpvZo130_assertion wasGeneratedBy ECO_0000203 NP658274.RAHeeYxZie7t2vMTs576rhCgue65nwwZCARQj5KpHpvZo130_provenance.